Table 2 mRNA vaccines against some emerging/re-emerging viruses.
Emerging viruses | Encoded antigen | Delivery system | Route | Protective response | References |
|---|---|---|---|---|---|
HCMV | gB, PC, pp65 | LNP | Intramuscular | T cells and Neutralizing antibodies | |
Rabies | Rabies virus glycoprotein | Protamine | Intramuscular and intradermal | T cells and Neutralizing antibodies | |
Ebola | Envelope glycoprotein | LNP | Intramuscular | Neutralizing antibodies | |
Zika | prM-E | LNP | Intramuscular | Neutralizing antibodies | 165 ClinicalTrials.gov/ |
NCT03014089 | |||||
Influenza | Hemagluttinin glycoprotein (H10N8 and H7N9) | LNP | Intramuscular and intradermal | T cells and neutralizing antibodies | |
HIV | HIV-1 Tat, Nef and Rev proteins | Autologous dendritic cells | Subcutaneous and intradermal | T cells | |
RSV | Fusion protein | LNP | Intramuscular | T cells and neutralizing antibodies | |
Dengue | PrM-E | LNP | – | T cells and neutralizing antibodies | |
Chikungunya | CHIKV structural polyprotein | – | Intramuscular | Neutralizing antibodies | |
NCT03325075 |
